IC
FULC icon

Ikarian Capital’s Fulcrum Therapeutics FULC Stock Holding History

Ikarian Capital’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-22,800
Closed -$81.4K – 188
2024
Q3 		$81.4K Buy
+22,800
New +$169K 0.01% 142

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Ikarian Capital's FULC Position: Q1 2026 in Review

Ikarian Capital reduced its Fulcrum Therapeutics (FULC) stake by 24% in Q1 2026, selling an estimated $3.03M and leaving 1,049,161 shares worth $8.05M. The position accounts for 0.65% of the portfolio, ranked #43.

Ikarian Capital first reported a position in FULC in Q4 2020 and has held it in 10 quarters since. The position peaked at $15.6M in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Ikarian Capital held 1,049,161 shares of Fulcrum Therapeutics worth $8.05M as of Q1 2026.
  • Ikarian Capital sold 326,311 Fulcrum Therapeutics shares in Q1 2026, an estimated $3.03M.
  • Fulcrum Therapeutics made up 0.65% of Ikarian Capital's portfolio in Q1 2026, its #43 holding.
  • Ikarian Capital first reported a position in Fulcrum Therapeutics in Q4 2020 and has held it in 10 quarters since.
  • Ikarian Capital's Fulcrum Therapeutics position peaked at $15.6M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.